• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 12th September 2019

Data Governance Arrangements for Real-world Evidence in Japan

A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how real-world data is accessed or generated and used to produce or generate real-world evidence,…

fallback-profile-image_1
Marina Rodes Sanchez
Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how real-world data is accessed or generated and used to produce or generate real-world evidence, and to see whether use is aligned with international standards.

A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how real-world data is accessed or generated and used to produce or generate real-world evidence, and to see whether use is aligned with international standards.

A 2015 OHE Consulting Report explored data governance arrangements for real-world evidence (RWE) in eight countries: Australia, France, Germany, Italy, Sweden, the Netherlands, the UK, and the US. The objective was to understand and develop a view on the core principles that should govern how real-world data (RWD) is accessed or generated and used credibly to produce or generate RWE, working toward a set of ‘international standards’. In 2017, Lilly commissioned a second report, on South Korea, following the same method and structure as the original.

For our latest report, information was collected by the Japanese co-authors Hideo Yasunaga and Hayato Yamana using the same pro-forma as for the previous reports. The report outlines the current arrangements for the collection, sharing, and use of RWD, and assesses how these compare with an ‘ideal’, facilitative framework for data governance.

The report briefly introduces the Japanese health system before presenting in more detail the arrangements behind the collection and management of patient data. In Japan, as well as other countries, academic studies using RWD have been increasing in number, and academic societies are using RWE to revise guidelines and to create medical decision tools useful in clinical practice. The Ministry of Health, Labour, and Welfare (MHLW) also uses RWD to support decisions on inclusion in universal healthcare coverage. The Pharmaceuticals and Medical Devices Agency has just started using RWD and RWE to monitor adverse drug events and to make regulatory decisions. Pharmaceutical companies are using commercially available RWD for post-marketing studies and for studies to better understand patients in order to improve drug development.

At present, various types of RWD are regularly collected by insurers and/or hospitals. Different entities – public or private, non-commercial or commercial – gather the data to create their own bigger, anonymised databases, which are made available to various recipients (some limited to selected academic researchers, others open to private companies). Sources of RWD include, but are not limited to, administrative claims data for healthcare services, national health check-up data, the Diagnosis Procedure Combination (DPC) data, and Electronic Medical Records.

In Japan, the legal framework for using personal data includes the Act on the Protection of Personal Information (APPI) and related government guidelines. The governance arrangements cover two important aspects. Firstly, patient consent for collecting and using routinely collected data. Under current conditions, most Japanese RWD are open only to academic researchers and societies, who don’t need to obtain prior individual patient consent, and are closed to the private sector (e.g. pharmaceutical companies and consulting companies), except for several commercially available databases which use de-identified patient data. Secondly, requirements for de-identification of routinely collected data. An option that allows more flexibility within the APPI is to obtain data through a de-identification process undertaken within the medical institution itself, so that patient data are no longer deemed to be personal information and are therefore no longer subject to the Act.

Japan is still facing some challenges in developing a clear set of nationally agreed and implemented standard rules to optimise interoperability of health system records. These limit the ability to fully benefit from achievements in the areas of de-identification, privacy rules, data control, and access. New legislation, the Next-generation Healthcare Infrastructure Act (NHIA), was put into force in 2018 with the potential to fundamentally change the governance arrangements for RWD in Japan. According to this law, “certified operators for de-identifying medical data” are allowed to collect patients’ personal information directly from healthcare providers, link all the data at the individual level, and provide de-identified data to academic researchers. The implication of this being that NHIA can improve individual-level data linkage which has the potential to enhance RWD studies. However, the MHLW is still searching for candidates to act as the certified operators, and thus the issue of data accessibility has not been fully addressed. It is unclear whether this new development will help deal with the asymmetry of the position of commercial and non-commercial researchers in getting access to RWD to conduct research.

Citation

Yasunaga, H., Yamana, H., Rodes Sanchez, M. and Towse, A., 2019. Data Governance Arrangements for Real-World Evidence in Japan. OHE Consulting Report, London: Office of Health Economics.

Related research

Hampson, G., Towse, A., Dreitlein, W.B., Henshall, C. and Pearson, S.D., 2018. Real-world Evidence for Coverage Decisions: Opportunities and Challenges. Journal of Comparative Effectiveness Research, 7(12), pp.1133-43. DOI. RePEc.

Lee,E.K., Park,J.A., Cole,A. and Mestre-Ferrandiz,J., 2017. Data Governance Arrangements for Real-World Evidence in South Korea. OHE Consulting Report, London: Office of Health Economics. RePEc.

Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A. 2015. Data Governance Arrangements for Real-World Evidence. OHE Consulting Report, London: Office of Health Economics. RePEc.

  • Drug Development/R&D
  • Economics of Innovation
  • Consulting Reports

Related News

  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
  • News
  • July 2020

NICE ‘Optimised’ Recommendations: What Do They Mean for Patient Access?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!